Recurrent Uti Clinical Trial
Official title:
Protocol 19-01: Canadian, Single Centre, Pilot, Open Label Study to Evaluate the Efficacy and Safety of the Bacterial Vaccine Uromune in Treating Recurrent Urinary Tract Infections in Women.
To determine the effectiveness and safety of the vaccine Uromune in Canadian women with recurrent urinary tract infection.
The proposal is for a real life clinical practice study in which female participants with a predefined history of recurrent UTIs in the previous year will be treated with 3 months of oral vaccine with a further 9 months of follow-up. The primary outcome will be no UTI in the 12 months following initiation of the vaccine (definition of a responder). A clinically significant and important outcome will be defined as a responder rate of 50% (50% of participants who had at least 3 UTIs in the previous year reporting no UTIs after therapy initiated. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT03210038 -
Cystoscopy in Females: Is There a Difference Between Rigid and Flex Cystoscopy, and Does it Require Local Anasthesia?
|
N/A | |
| Completed |
NCT03644966 -
Probiotics and Multi-Drug Resistant Urinary Tract Infection
|
N/A | |
| Recruiting |
NCT06149676 -
A Novel Probiotic-antibiotic Combination to Prevent Recurrent Urinary Tract Infections
|
Early Phase 1 | |
| Not yet recruiting |
NCT06332781 -
Intravesical Gentamicin to Prevent Recurrent UTI
|
Phase 4 |